In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Survodutide | Synthetic analog Tirzepatide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 172 | 2,165 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 37 (37 in people) | 462 (462 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 35 · 10 active1 more mentions it but does not test it | 254 · 162 active47 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Survodutide | Tirzepatide |
|---|---|---|
| Body weightMetabolic and weight | 42384 | 52150118 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Mounjaro says: “Adjunct to diet and exercise for glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes; reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for these events”
| Glycemic controlMetabolic and weight | 30237 | 36435581 |
|---|
| Adverse eventsWhole body | 2424 | 213213 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 1212 | 179179 |
|---|
| Liver fat and liver functionLiver | 29281 | 5353 |
|---|
| LipidsCardiovascular | 22 | 79763 |
|---|
| MortalityWhole body | 11 | 635724 |
|---|
| Blood pressureCardiovascular | 11 | 5151 |
|---|
| Kidney functionKidney and urinary | 66 | 40391 |
|---|
| Inflammation markersKidney and urinary | 11 | 41347 |
|---|
| Appetite and food intakeNervous system and cognition | 22 | 20191 |
|---|
| PharmacokineticsPharmacology | 33 | 16133 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Survodutide differs from Glucagon at 9 positions.
What is different
Tirzepatide differs from Gastric inhibitory polypeptide (GIP) at 11 positions and in 1 end segment.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 35 trials, ranked by phase, then posted results and enrollment: 2 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)
Boehringer Ingelheim5,531 participants20 Nov 2023 to 30 Jun 2026
Obesity
Boehringer Ingelheim1,800 participants14 Oct 2024 to est. 27 Dec 2031
Metabolic Dysfunction Associated Steatohepatitis (MASH) · Liver Fibrosis
Boehringer Ingelheim1,590 participants12 Nov 2024 to est. 5 Jun 2029
Metabolic Dysfunction Associated Steatohepatitis
1 more mentions it but does not test it. They only measure it or name it in their text.
Top 3 of 254 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Eli Lilly and Company13,299 participants29 May 2020 to 12 Jun 2025
Type 2 Diabetes Mellitus
Eli Lilly and Company2,539 participants4 Dec 2019 to 6 Jul 2024
Overweight · Obesity
Eli Lilly and Company2,002 participants20 Nov 2018 to 22 Apr 2021
Type 2 Diabetes Mellitus
47 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Survodutide | Tirzepatide |
|---|---|---|
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in % | −12.2% Mean body weight change · survodutide 3.6 mg Placebo: −5.4% Dose studied: up to 3.6 mg once weekly76 weeksn not reported2026 | −20.9% Mean percentage weight reduction at week 72 · Shown as a change. The study reports a mean percentage weight reduction at week 72 of this size. · tirzepatide 15 mg Placebo: −3.1% Dose studied: 5 mg, 10 mg or 15 mg once weekly72 weeks, including a 20-week dose-escalation periodn = 2,5392022 |
| Glycemic controlMetabolic and weightCompared as: value in the arm that got the peptide, in percentage points | −0.9 percentage points HbA1c change · survodutide 3.6 mg Placebo: −0.2 percentage points Dose studied: 3.6 mg once weeklyn not reported2026 | |
| Gastrointestinal adverse eventsGastrointestinalCompared as: share of people in the arm that got the peptide, in % | 49% Diarrhea incidence Placebo: 23% Dose studied: 2.4, 4.8 or 6.0 mg once weekly48 weeksn = 2932024 | 12 to 21% Diarrhea incidence Placebo: 10% Dose studied: 5 mg, 10 mg or 15 mg once weekly (started at 2.5 mg/week, escalated by 2.5 mg every 4 weeks) |
| Adverse eventsMetabolic and weightCompared as: value in the arm that got the peptide, in % | 8% Serious adverse events Placebo: 7% Dose studied: 2.4, 4.8 or 6.0 mg once weekly48 weeksn = 2932024 | 5 to 7% Serious adverse events Dose studied: 5, 10 or 15 mg once weekly40 weeksn not reported |
−12.2%
Mean body weight change · survodutide 3.6 mg
Placebo: −5.4%
Dose studied: up to 3.6 mg once weekly76 weeksn not reported2026
−20.9%
Mean percentage weight reduction at week 72 · Shown as a change. The study reports a mean percentage weight reduction at week 72 of this size. · tirzepatide 15 mg
Placebo: −3.1%
Dose studied: 5 mg, 10 mg or 15 mg once weekly72 weeks, including a 20-week dose-escalation periodn = 2,539
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Survodutide | Tirzepatide |
|---|---|---|
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in days | No comparable result 1 randomized-trial result measure it in another way or another unit. | ≈ 5 days Half-life Dose studied: 5, 10 or 15 mg8 weeksn = 482022 |
−1.99 percentage points
HbA1c change
Dose studied: 15 mg or maximum tolerated dose2 yearsn = 7942026
−0.9 percentage points
HbA1c change · survodutide 3.6 mg
Placebo: −0.2 percentage points
Dose studied: 3.6 mg once weeklyn not reported2026
−1.99 percentage points
HbA1c change
Dose studied: 15 mg or maximum tolerated dose2 yearsn = 7942026
49%
Diarrhea incidence
Placebo: 23%
Dose studied: 2.4, 4.8 or 6.0 mg once weekly48 weeksn = 2932024
12 to 21%
Diarrhea incidence
Placebo: 10%
Dose studied: 5 mg, 10 mg or 15 mg once weekly (started at 2.5 mg/week, escalated by 2.5 mg every 4 weeks)40 weeksn = 4752022
8%
Serious adverse events
Placebo: 7%
Dose studied: 2.4, 4.8 or 6.0 mg once weekly48 weeksn = 2932024
5 to 7%
Serious adverse events
Dose studied: 5, 10 or 15 mg once weekly40 weeksn not reported2021
| Liver fat and liver functionLiverCompared as: share of people in the arm that got the peptide, in % | 47% MASH improvement responders · survodutide 2.4 mg Placebo: 14% Dose studied: 2.4 mg once weekly48 weeksn not reported2024 | No comparable result 15 randomized-trial results measure it in another way or another unit. |
|---|
| Appetite and food intakeMetabolic and weightCompared as: difference from placebo, in kcal | No randomized trial result 2 results from other study designs. | −524.6 kcal Estimated treatment difference n not reported2025 |
|---|
| Blood pressureCardiovascularCompared as: difference from placebo, in mm hg | No randomized trial result 1 result from other study designs. | −6.8 mm Hg Net systolic blood pressure reduction · Shown as a change. The study reports a net systolic blood pressure reduction of this size. 72 weeksn not reported2024 |
|---|
| Kidney functionKidney and urinaryCompared as: value in the arm that got the peptide, in % | No randomized trial result 6 results from other study designs. | −19.3% UACR percent change · tirzepatide 5 mg Dose studied: 5 mgweek 40/42n not reported2025 |
|---|
| LipidsMetabolic and weightCompared as: value in the arm that got the peptide, in % | No randomized trial result 2 results from other study designs. | ≤ 22.9% Variability in triglyceride change explained by apoC-III change Dose studied: 1, 5, 10 or 15 mg once weekly26 weeksn not reported2020 |
|---|
No comparable result
1 randomized-trial result measure it in another way or another unit.
≈ 5 days
Half-life
Dose studied: 5, 10 or 15 mg8 weeksn = 482022
47%
MASH improvement responders · survodutide 2.4 mg
Placebo: 14%
Dose studied: 2.4 mg once weekly48 weeksn not reported2024
No comparable result
15 randomized-trial results measure it in another way or another unit.
No randomized trial result
2 results from other study designs.
−524.6 kcal
Estimated treatment difference
n not reported2025
No randomized trial result
1 result from other study designs.
−6.8 mm Hg
Net systolic blood pressure reduction · Shown as a change. The study reports a net systolic blood pressure reduction of this size.
72 weeksn not reported2024
No randomized trial result
6 results from other study designs.
−19.3%
UACR percent change · tirzepatide 5 mg
Dose studied: 5 mgweek 40/42n not reported2025
No randomized trial result
2 results from other study designs.
≤ 22.9%
Variability in triglyceride change explained by apoC-III change
Dose studied: 1, 5, 10 or 15 mg once weekly26 weeksn not reported2020